Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Immunitas Therapeutics
Arcus Biosciences, Inc.
Washington University School of Medicine
Zumutor Biologics Inc.
Washington University School of Medicine
University Medical Center Groningen
Celldex Therapeutics
CytomX Therapeutics
Hospices Civils de Lyon
Incyte Corporation
MultiVir, Inc.
Shenzhen BinDeBio Ltd.
Tel-Aviv Sourasky Medical Center
Ohio State University Comprehensive Cancer Center
Valerio Therapeutics
INSYS Therapeutics Inc
National Cancer Institute (NCI)
Altor BioScience
National Cancer Institute (NCI)
Ontario Clinical Oncology Group (OCOG)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Utah
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Case Comprehensive Cancer Center